These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 809532)

  • 1. Inhibition of T-lymphocyte-mediated tumor-specific lysis by alloantisera directed against the H-2 serological specificities of the tumor.
    Germain RN; Dorf ME; Benacerraf B
    J Exp Med; 1975 Oct; 142(4):1023-8. PubMed ID: 809532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T lymphocytes specific for I region determinants do not require interactions with H-2K or D gene products.
    Billings P; Burakoff S; Dorf ME; Benacerraf B
    J Exp Med; 1977 May; 145(5):1387-92. PubMed ID: 67179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
    Plata F; Jongeneel V; Cerottini JC; Brunner KT
    Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T lymphocytes induced against allogeneic I-region determinants react with Ia molecules on trinitrophenyl-conjugated syngeneic target cells.
    Billings P; Burakoff S; Dorf ME; Benacerraf B
    J Exp Med; 1977 Aug; 146(2):623-8. PubMed ID: 69009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T-cell response to Ectromelia virus-infected cells. Different H-2 requirements for triggering precursor T-cell induction or lysis by effector T cells defined by the BALB/c-H-2db mutation.
    Blanden RV; McKenzie IF; Kees U; Melvold RW; Kohn HI
    J Exp Med; 1977 Sep; 146(3):869-80. PubMed ID: 70498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cell-mediated cytolysis of trinitrophenyl-derivatized target cells by alloantisera directed to the products of the K and D loci of the H-2 complex.
    Burakoff SJ; Germain RN; Dorf ME; Benacerrah B
    Proc Natl Acad Sci U S A; 1976 Feb; 73(2):625-9. PubMed ID: 1082140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exclusive involvement of H-2Db or H-2Kd product in the interaction between T-killer lymphocytes and syngeneic H-2b or H-2d viral lymphomas.
    Gomard E; Duprez V; Reme T; Colombani MJ; Levy JP
    J Exp Med; 1977 Oct; 146(4):909-22. PubMed ID: 197198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple H-2 linked immune response gene control of H-2 D-associated T-cell-mediated lympholysis to trinitrophenyl-modified autologous cells: Ir-like genes mapping to the left of I-A and within the I region.
    Schmitt-Verhulst AM; Shearer GM
    J Exp Med; 1976 Dec; 144(6):1701-6. PubMed ID: 1087329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Participation of the H-2 antigens of tumor cells in their lysis by syngeneic T cells.
    Schrader JW; Edelman GM
    J Exp Med; 1976 Mar; 143(3):601-14. PubMed ID: 1082492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the induction of cytolytic T lymphocytes with alloantisera directed against H-2K and H-2D gene products.
    Lemonnier F; Burakoff SJ; Mescher M; Dorf ME; Benacerraf B
    J Immunol; 1978 May; 120(5):1717-20. PubMed ID: 307020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of I region-restricted hapten-specific cytotoxic T lymphocytes.
    Wagner H; Starzinski-Powitz A; Jung H; Röllinghoff M
    J Immunol; 1977 Oct; 119(4):1365-8. PubMed ID: 302282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloimmune cytotoxic T cells: Evidence that they recognize serologically defined antigens and bear clonally restricted receptors.
    Bevan MJ
    J Immunol; 1975 Jan; 114(1 Pt 2):316-9. PubMed ID: 123256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition of Rous sarcoma virus-induced tumor antigens by cytotoxic T lymphocytes (CTL): studies on specificity of killing by CTL employing H-2 congenic and recombinant mouse tumor cells.
    Haraguchi S; Kurakata S; Fujii T; Matsuo T; Yoshida TO
    Cell Immunol; 1987 Apr; 105(2):340-54. PubMed ID: 2436809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
    J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of T-cell-mediated lympholysis by the murine major histocompatibility complex. I. Preferential in vitro responses to trinitrophenyl-modified self K- and D-coded gene products in parental and F1 hybrid mouse strains.
    Levy RB; Shearer GM
    J Exp Med; 1979 Jun; 149(6):1379-92. PubMed ID: 109568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
    Weinhold KJ; Wheelock EF
    Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor immunity to murine plasma cell tumors. VII. Expression of H-2 and tumor antigens on Ig synthesis variants of MPC-11.
    Giorgi JV; Burton RC; Scott D; Warner NL
    Int J Cancer; 1982 Jan; 29(1):119-26. PubMed ID: 6977499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-mediated lympholysis of trinitrophenyl-modified autologous lymphocytes. Effector cell specificity to modified cell surface components controlled by H-2K and H-2D serological regions of the murine major histocompatibility complex.
    Shearer GM; Rehn TG; Garbarino CA
    J Exp Med; 1975 Jun; 141(6):1348-64. PubMed ID: 47900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
    Carayanniotis G; Halloran PF
    Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.